Likarda
Tuesday, February 27, 2024
Uris
Platform for Therapeutics
Likarda has pioneered a groundbreaking platform for hydrogel delivery systems, offering both long- and short-term solutions that can either provide complete immuno-protection or degrade gradually. This innovation enables precise localized therapy delivery without the need for immunosuppression, effectively addressing critical gaps in cell therapy. Our CSS Platform significantly enhances therapy efficacy by targeting specific areas, reducing off-target effects, and minimizing the required cell numbers for a therapeutic dose. In essence, Likarda's innovative hydrogel platform revolutionizes cell therapy delivery, addressing challenges in storage, shipping, and targeted delivery while offering scalable, cost-effective solutions.
Speakers
State
Missouri
Country
United States
Website
http://www.likarda.com
CEO/Top Company Official
Stella K. Vnook, PhD
Lead Product in Development
Cell therapy delivery system for osteoarthritis and cancer.
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
5 Animal Health Products and 2 Human Health Products
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}